Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
04/07/2025 | Q4 2024 | N/A | -$0.09 | N/A | N/A | $0 |
09/30/2024 | Q3 2024 | N/A | -$0.11 | N/A | N/A | $0 |
09/30/2024 | Q2 2024 | N/A | -$0.05 | N/A | N/A | $0 |
03/30/2024 | Q1 2024 | N/A | -$0.35 | N/A | N/A | $0 |
04/04/2024 | Q4 2023 | N/A | -$0.19 | N/A | N/A | $0 |
09/29/2023 | Q3 2023 | N/A | $0.06 | N/A | N/A | $0 |
06/30/2023 | Q2 2023 | N/A | -$0.38 | N/A | N/A | $0 |
04/17/2023 | Q1 2023 | N/A | -$0.25 | N/A | N/A | $0 |
03/22/2023 | Q4 2022 | N/A | -$0.25 | N/A | N/A | $0 |
09/30/2022 | Q3 2022 | N/A | -$0.23 | N/A | N/A | $0 |
01/19/2023 | Q2 2022 | N/A | -$0.30 | N/A | N/A | $0 |
03/31/2022 | Q1 2022 | N/A | -$0.24 | N/A | N/A | $0 |
04/14/2022 | Q4 2021 | N/A | -$0.01 | N/A | N/A | $0 |
09/30/2021 | Q3 2021 | N/A | -$0.08 | N/A | N/A | $0 |
06/30/2021 | Q2 2021 | N/A | -$0.08 | N/A | N/A | $0 |
03/31/2021 | Q1 2021 | N/A | -$0.19 | N/A | N/A | $0 |
12/31/2020 | Q4 2020 | N/A | -$0.20 | N/A | N/A | $0 |
09/29/2020 | Q3 2020 | N/A | -$0.20 | N/A | N/A | $0 |
06/29/2020 | Q2 2020 | N/A | -$0.06 | N/A | N/A | $0 |
03/30/2020 | Q1 2020 | N/A | -$0.06 | N/A | N/A | $0 |
NeuroSense Therapeutics Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 27th, 2025 based offlast year's report dates.
The conference call for NeuroSense Therapeutics Ltd.'s latest earnings report can be listened to online.
The conference call transcript for NeuroSense Therapeutics Ltd.'s latest earnings report can be read online.
NeuroSense Therapeutics Ltd. (:NRSNW) has a recorded net income of $-10,210,000.NeuroSense Therapeutics Ltd. has generated $-0.55 earnings per share over the last four quarters.
NeuroSense Therapeutics Ltd. (:NRSNW) has a price-to-earnings ratio of -5.57 and price/earnings-to-growth ratio is -0.39.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED